Back to News
Market Impact: 0.3
Genmab's Potesemtamab Plus Pembrolizumab Shows 28-Month Survival In Head And Neck Cancer
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Genmab reported updated Phase 2 results showing encouraging survival and response rates for potesemtamab plus pembrolizumab in first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma. The article provides no numerical efficacy data or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
GMAB0.65
More News
- Genmab shares jump 13% on colorectal cancer drug trial results
- Genmab's Encouraging Oncology Data Boosts Investor Optimism
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis